

EFFECTS OF AVEMAR® TREATMENT ON QUALITY OF LIFE IN TERMINAL LUNG CANCER

Center: Korányi National Institute of Tbc and Pulmonology, Budapest
Principal investigator: Dr. Zoltán Ajkay MD, General Director of Institute
Duration of study: 1999-2000
Number of patients: 17
Mean duration of Avemar treatment: 7.9 months
Diagnosis: SCLC (4 pts); NSCLC (13 pts)
Treatments: chemo- and radiotherapy (5 pts); chemotherapy alone (9 pts); palliative therapy (3 pts).

Results

Quality components

<u>Functional scales</u>	Significancy
Physical functions	N.S
Daily activity at home	N.S.
Emotional functions	N.S.
Cognitive functions	N.S.
Social functions	P<0.018
Global state of health	P<0.003
<u>Symptomatic scales</u>	
Fatigue	P<0.023
Nausea, vomiting	N.S.
Pain	N.S.
Dyspnoe	N.S.
Insomnia	N.S.
Asitia	N.S.
Constipation	P<0,045
Diarrhoea	N.S.
Financial problems	N.S.

Conclusions: Supportive Avemar treatment of terminal lung cancer patients resulted in significant improvements of several components of quality of life.